US Patent

US8999638 — Method of treatment based on polymorphisms of the KCNQ1 gene

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2030-10-28 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for administering compounds that prolong a QTc interval and predicting individual predisposition to such prolongation.

USPTO Abstract

The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1674 — Fanapt
U-1674 — Fanapt
U-1674 — Fanapt
U-1674 — Fanapt
U-4436 — milsaperidone
U-4436 — milsaperidone
U-4436 — milsaperidone
U-4436 — milsaperidone
U-4436 — milsaperidone
U-4436 — milsaperidone
U-1674 — Fanapt
U-1674 — Fanapt
U-4436 — milsaperidone
U-1674 — Fanapt

Patent Metadata

Patent number
US8999638
Jurisdiction
US
Classification
Method of Use
Expires
2030-10-28
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.